Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) Transcript
Welcome and good afternoon. Thanks, everybody, once again for joining us at the 42nd Annual Cowen Healthcare Conference. I'm Yaron Werber, one of the biotech analyst at Cowen. And it's a great pleasure to moderate the orphan CNS therapies panel with my colleagues, Brendan Smith and Lyla Youssef. We really have a terrific lineup today and a lot to talk about. We have from Annexon, Doug Love, who's the CEO; Geoff MacKay, who's the CEO of AVROBIO; we have Bobby Gaspar, who's the CEO of Orchard; Bruce Goldsmith, who's the CEO of Passage Bio; Emil Kakkis, who's the President and CEO of Ultragenyx; and Arnon Rosenthal, who is the CEO of Alector is going to be joining momentarily. So welcome, everybody, and thanks for joining us. We appreciate it.
So let's start. What we're going to do is we're going to talk first about a couple of maybe very broad drug development topics in orphan neurology, and then we'll do a round robin and dive into each company specifically. Most of you are developing drugs
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |